aTyr Pharma Inc
NASDAQ:ATYR

Watchlist Manager
aTyr Pharma Inc Logo
aTyr Pharma Inc
NASDAQ:ATYR
Watchlist
Price: 3.91 USD -1.51%
Market Cap: 328.2m USD
Have any thoughts about
aTyr Pharma Inc?
Write Note

P/E
Price to Earnings

-5.1
Current
-4
Median
21.3
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-5.1
=
Market Cap
328.2m USD
/
Net Income
-63.8m USD
All Countries
Close
Market Cap P/E
US
aTyr Pharma Inc
NASDAQ:ATYR
328.2m USD -5.1
FR
Pharnext SCA
OTC:PNEXF
6T USD -181 607.6
US
Abbvie Inc
NYSE:ABBV
315.6B USD 62.1
US
Amgen Inc
NASDAQ:AMGN
140.4B USD 33.2
US
Gilead Sciences Inc
NASDAQ:GILD
113.3B USD 899.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.2B USD -218.1
US
Epizyme Inc
F:EPE
94.1B EUR -470.5
AU
CSL Ltd
ASX:CSL
138.1B AUD 32.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.2B USD 17.3
US
Seagen Inc
F:SGT
39.3B EUR -54.5
NL
argenx SE
XBRU:ARGX
37.3B EUR -343.4
Earnings Growth PEG
US
aTyr Pharma Inc
NASDAQ:ATYR
Average P/E: 208.9
Negative Multiple: -5.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 607.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
62.1
72%
0.9
US
Amgen Inc
NASDAQ:AMGN
33.2
20%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
899.2
21%
42.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -218.1
14%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -470.5 N/A N/A
AU
CSL Ltd
ASX:CSL
32.6
18%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
13%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.5 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -343.4 N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-4.2
2-Years Forward
P/E
-4.8
3-Years Forward
P/E
-6.1